Clinical trials: Advanced Malignant Tumor
Advanced Solid Tumor
A Dose Finding Study of XRP6258 in Patients With Advanced Solid Tumors
Primary Objective: To determine the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of XRP6258 when given as a weekly 1-hour intravenous (i.v.) infusion for the first 4 consecutive weeks of each 5-week treatment…
- Trial name
- NCT01755390
- Testing
- Cabazitaxel (XRP6258)
- Where
- 2 sites in France, Spain
- Volunteers
- 42 people
- Sponsor
- Sanofi
Breast Cancer, Colorectal Cancer
A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced Malignancies
This is a Phase 2, open-label, multicenter study whose principal objectives are to evaluate the efficacy and safety/tolerability of poziotinib in five cohorts of 30 previously-treated patients each.
- Conditions
- Breast Cancer, Colorectal Cancer, Solid Tumor, Glioblastome Multiforme
- Trial name
- NCT04172597
- Testing
- Poziotinib Hydrochloride, Loperamide
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Spectrum Pharmaceuticals, Inc
Tumor Infiltrating Lymphocytes, Safety
A Phase I Study of GC101 TIL in Advanced Solid Tumors
20-60 participants are expected to be enrolled for the Phase I clinical trial which is further divided into two parts: a "3+3" dose escalation study and an expanded enrollment study.
- Conditions
- Tumor Infiltrating Lymphocytes, Safety, Advanced Solid Tumor, Immunotherapy
- Trial name
- MIZAR-001 (NCT05417750)
- Testing
- TIL therapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai Juncell Therapeutics
Advanced Solid Tumor, Metastatic Solid Tumor
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in…
- Trial name
- NCT06108050
- Testing
- JZP898, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals
Solid Tumor
Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors
To evaluate CAN1012 when administered by IT injection to subjects with advanced solid tumors who are not candidates for standard therapy.
- Trial name
- NCT05580991
- Testing
- CAN1012
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Canwell Biotech Limited
Solid Tumor, Adult, Colorectal Cancer
Study of IK-595 in RAS- or RAF-altered Advanced Tumors
This is a Phase 1, FIH, Dose Escalation and Dose Expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) effects, and preliminary antitumor activity of IK-595, a MEK/RAF molecular glue…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma
- Trial name
- NCT06270082
- Testing
- IK-595
- Where
- 15 sites in United States
- Volunteers
- 75 people
- Sponsor
- Ikena Oncology
Solid Tumor, Non Small Cell Lung Cancer
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
This is a phase I, First-in-Human (FIH), open-label study to evaluate the safety, tolerability, pharmacokinetic (PK) profile, and preliminary efficacy of AB248 as monotherapy OR in combination with pembrolizumab in adult…
- Conditions
- Solid Tumor, Non Small Cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT05653882
- Testing
- etakafusp alfa (AB248), pembrolizumab
- Where
- 20 sites in United States
- Volunteers
- 552 people
- Sponsor
- Asher Biotherapeutics, Inc.
Solid Tumor
A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors
The proposed clinical study is a Phase 1/2a trial to investigate the safety, tolerability, pharmacokinetics and clinical activity of anti-HLA-G CAR-T cells IVS-3001 administered to subjects with previously treated, locally…
- Trial name
- NCT05672459
- Testing
- Single Injection of IVS-3001- Anti - HLA-G CAR-T cells, Fludarabine phosphate, Cyclophosphamide
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Ovarian Neoplasms
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Endometrial Cancer
- Trial name
- NCT05001282
- Testing
- ELU001
- Where
- 18 sites in United States
- Volunteers
- 79 people
- Sponsor
- Elucida Oncology
Advanced Solid Tumors Cancer
Autologous Tumor Infiltrating Lymphocyte (TIL) GT201 Infusion.
This is a multicenter, single-arm phase 1/2 clinical trial to evaluate the safety and tolerability of GT201 as a monotherapy or in combination with anti-PD-1 therapy in patients with advanced solid tumors, and to evaluate the…
- Trial name
- GT201 (NCT07766317)
- Testing
- GT201, IL-2 and PD-1
- Volunteers
- 63 people
- Sponsor
- Gritbio Medicine, Inc.
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8
Entinostat, Nivolumab, and Ipilimumab in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Locally Advanced or Metastatic HER2-Negative Breast Cancer
This phase I trial studies the side effects and best dose of entinostat and nivolumab when given together with ipilimumab in treating patients with solid tumors that have spread to other places in the body and usually cannot be…
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma
- Trial name
- NCT02453620
- Testing
- Biopsy Procedure, Blood Sample, Bone Scan
- Where
- 5 sites in United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Everolimus Post Pazopanib Treatment in Metastatic or Advanced Renal Cell Carcinoma
Study to determine the efficacy, safety and tolerability of first-line pazopanib followed by second-line everolimus in metastatic and advanced renal cell carcinoma.
- Trial name
- CATChEz (NCT01545817)
- Testing
- Pazopanib followed by everolimus
- Where
- 15 sites in Australia, South Korea
- Volunteers
- 74 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
This phase II Pediatric MATCH trial studies how well palbociclib works in treating patients with Rb positive solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with activating alterations (mutations) in cell cycle genes…
- Conditions
- Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma, Recurrent Ewing Sarcoma, Recurrent Glioma
- Trial name
- NCT03526250
- Testing
- Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study
- Where
- 117 sites in United States, Puerto Rico
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1
Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin
This phase II trial studies how well ribociclib works in treating patients with neuroendocrine tumors of the foregut, which includes the thymus, lung, stomach, and pancreas, that have spread to other places in the body and…
- Conditions
- Advanced Digestive System Neuroendocrine Neoplasm, Duodenal Neuroendocrine Tumor G1, Functional Pancreatic Neuroendocrine Tumor, Gastric Neuroendocrine Tumor
- Trial name
- NCT02420691
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Ribociclib
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Tumor, Solid, Lymphoma
GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma
This is a Phase I clinical study for evaluating the safety, pharmacokinetics, and preliminary efficacy of repeated doses, dose escalation of GR1405 injection in patients with advanced solid tumor or lymphoma
- Trial name
- NCT03731390
- Testing
- GR1405 injection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chinese Academy of Medical Sciences
Solid Tumors and Hematologic Malignancy
A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients
This is an open-label, multicenter, non-randomized, dose escalation and tumor-expansion phase I trial to evaluate safety and tolerability of INCSHR01210 in patients with advanced solid tumors.
- Trial name
- NCT02492789
- Testing
- INCSHR01210 injection
- Where
- 5 sites in Australia
- Volunteers
- 49 people
- Sponsor
- Atridia Pty Ltd.
Advanced Cancer
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors
This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.
- Trial name
- NCT07291050
- Testing
- TQB3217Tablets
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Solid Tumor, NSCLC
SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET
This is a first-in-human, multicenter, open-label Phase 1/2 study designed to evaluate the safety, efficacy, and tolerability of [225Ac]Ac-FL-261, a targeted radioligand therapy directed at c-MET, in participants with advanced or…
- Conditions
- Solid Tumor, NSCLC, Colorectal Cancer, Head and Neck Cancer
- Trial name
- NCT07873450
- Testing
- [225Ac]Ac-FL-261
- Where
- 2 sites in United States, Australia
- Volunteers
- 208 people
- Sponsor
- Full-Life Technologies UK Limited
Solid Tumor, Unspecified, Adult
The Safety and Dosimetry Study of 177Lu-LNC1004 Injection
This proposal is a phase I, open-label study of a 4-Dose Regimen of Escalating Doses of 177Lu-LNC1004 Injection in patients with recurrent or metastatic, fibroblast activation protein-positive solid tumors.
- Trial name
- NCT05723640
- Testing
- 177Lu-LNC1004 Injection group 1 radionuclide therapy, 177Lu-LNC1004 Injection group 2 radionuclide therapy, 177Lu-LNC1004 Injection group 3 radionuclide therapy
- Where
- Singapore
- Volunteers
- 11 people
- Sponsor
- Yantai LNC Biotechnology Singapore PTE. LTD.
Metastatic Cancer, Solid Tumor
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma
- Conditions
- Metastatic Cancer, Solid Tumor, Advanced Cancer, NonHodgkin Lymphoma
- Trial name
- NCT03013218
- Testing
- Evorpacept (ALX148), Pembrolizumab, Trastuzumab
- Where
- 10 sites in United States, South Korea
- Volunteers
- 174 people
- Sponsor
- ALX Oncology Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.